Arcutis Biotherapeutics (ARQT): Officer filed to sell ~$1.37M
Masaru Matsuda, Officer at Arcutis Biotherapeutics, filed to sell ~$1.37M of Arcutis Biotherapeutics shares.
- ~$1.37M
- planned to sell · 40K shares, around Nov 4, 2026
- Planned for
- Nov 4, 2026
- Notice filed
- Nov 4, 2026
What stands out in this filing
- The planned sale is 0.03% of the company's shares outstanding, as stated on the notice.
- How the shares were acquired, per the notice: Stock Option Exercise.
- The notice says the shares were received as pay (stock awards or options).
- Broker named on the notice: Merrill Lynch.
- A Form 144 announces a sale; the Form 4 that follows shows whether it took place, at what price.
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Oct 5, 20265% stakeBlackRock, Inc. reported a passive stake (13G) of 14.1%
- Oct 15, 2026InsiderDirector sold ~$127K of ARQT shares in the open market
- Oct 23, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On October 23, 2026, the Board of Directors (the “Board”) of Arcutis Biotherapeutics, Inc. (the “Company”) increased the authorized number of directors on the Board from ten to eleven directors and appointed Dr. Robert Scott as a new member of the Board and the Nominating and Corporate Governance Committee of the Board.”
- Nov 2, 2026Insider · 3 peopleInsiders: 3 sales (~$208K)
- Nov 4, 2026Company filing · Form 8-K · ResultsReported its results
- Nov 4, 2026Insider · Their largest sale since 2022Officer sold ~$1.37M of ARQT shares in the open market
What came next
How to read SEC Form 144
Form 144 is a notice that a company insider plans to sell shares. It is filed when the sell order is placed, so it announces a planned sale and does not prove that the sale took place.
Full guide: What is an SEC Form 144?
What else is on file for Arcutis Biotherapeutics
For Arcutis Biotherapeutics, OQRO holds 13 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ARQT page.
How this filing works
Explore the data
Common questions
Which Arcutis Biotherapeutics (ARQT) insider traded, and how much?
Masaru Matsuda, Officer at Arcutis Biotherapeutics, filed to sell ~$1.37M of Arcutis Biotherapeutics shares. 40K shares, Form 144 notice of a planned sale.
When did it happen, and when was it made public?
Planned for: Nov 4, 2026. Notice filed: Nov 4, 2026.
What stands out in this filing?
The planned sale is 0.03% of the company's shares outstanding, as stated on the notice. How the shares were acquired, per the notice: Stock Option Exercise. The notice says the shares were received as pay (stock awards or options).
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 144, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Arcutis Biotherapeutics recently?
For Arcutis Biotherapeutics, OQRO holds 13 insider filings (SEC Form 4 or Form 144) dated in the last 90 days. They are listed on the ARQT page.
Does this mean ARQT stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Arcutis Biotherapeutics
- SEC Form 4Nov 18, 2026
- SEC Form 144Nov 16, 2026
- SEC Form 4Nov 4, 2026
- SEC Form 4Nov 4, 2026
- SEC Form 4Nov 4, 2026
- SEC Form 4Nov 4, 2026
Everything OQRO holds on this company is on its ARQT page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
